Schering-Plough Puffs Up Asthma Line With Foradil From Novartis
Executive Summary
Schering-Plough is plugging a hole in its asthma product line by in-licensing Novartis' Foradil
You may also be interested in...
Asmanex/Foradil combo development
Schering-Plough and Novartis will develop Asmanex/Foradil combination product to treat asthma and chronic obstructive pulmonary disorder, the companies announced April 10. Schering's pending NDA for Asmanex (mometasone) was submitted Nov. 30, 1998. In November 2002, Schering acquired U.S. marketing rights to Novartis' Foradil (formoterol) (1"The Pink Sheet" Nov. 4, 2002, p. 22)...
Asmanex/Foradil combo development
Schering-Plough and Novartis will develop Asmanex/Foradil combination product to treat asthma and chronic obstructive pulmonary disorder, the companies announced April 10. Schering's pending NDA for Asmanex (mometasone) was submitted Nov. 30, 1998. In November 2002, Schering acquired U.S. marketing rights to Novartis' Foradil (formoterol) (1"The Pink Sheet" Nov. 4, 2002, p. 22)...
Subutex/Suboxone Prescriber Registration Efforts Ramping Up After Approval
The Substance Abuse & Mental Health Services Administration is working to register physicians to prescribe Schering-Plough/Reckitt Benckiser's opioid addiction treatment therapies Subutex and Suboxone in advance of the products' launch